Mesoblast (MESO) Short term Debt (2018 - 2026)
Mesoblast (MESO) posted Short term Debt of $66.7 million for Q4 2025, down 1.48% sequentially from $67.7 million in Q2 2025, and down 34.23% YoY from $101.5 million in Q4 2024.
Analysis
Mesoblast (MESO) Short term Debt (2018 - 2026) Analysis & Trends
Mesoblast has reported Short term Debt for 8 years, with the latest figure at $66.7 million in Q4 2025.
- Quarterly Short term Debt fell 34.23% year-over-year to $66.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $66.7 million (down 34.23% YoY) and the FY2025 annual result came in at $67.7 million, up 388.67% from the prior year.
- Short term Debt declined to $66.7 million in Q4 2025 per MESO's latest filing, from $67.7 million in the prior quarter.
- Over five years, Short term Debt peaked at $107.2 million in Q4 2023 and troughed at $5.0 million in Q2 2022.
- A 5-year average of $67.1 million and a median of $77.1 million in 2021 frame the typical range for Short term Debt.
- The sharpest annual moves came in 2022 and 2025: Short term Debt sank 90.57% in 2022, then jumped 388.67% in 2025.
- Over 5 years, Short term Debt stood at $86.5 million in 2021, then grew by 12.07% to $97.0 million in 2022, then grew by 10.56% to $107.2 million in 2023, then declined by 5.37% to $101.5 million in 2024, then plunged by 34.23% to $66.7 million in 2025.
- According to Business Quant data, Short term Debt over the past three periods registered $66.7 million, $67.7 million, and $101.5 million for Q4 2025, Q2 2025, and Q4 2024 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Mesoblast | 2.24 Bn | 2.14 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 10.60 Mn |
| Dec 31, 2025 | 66.74 Mn |
| Jun 30, 2025 | 54.16 Mn |
| Dec 31, 2024 | 17.51 Mn |
| Jun 30, 2024 | 13.86 Mn |
| Dec 31, 2023 | 8.53 Mn |
| Jun 30, 2023 | 5.95 Mn |
| Mar 31, 2023 | 7.31 Mn |
| Dec 31, 2022 | 5.94 Mn |
| Sep 30, 2022 | 5.49 Mn |
| Jun 30, 2022 | 5.02 Mn |
| Mar 31, 2022 | 5.52 Mn |
| Dec 31, 2021 | 5.20 Mn |
| Sep 30, 2021 | 53.85 Mn |
| Jun 30, 2021 | 53.20 Mn |
| Mar 31, 2021 | 52.67 Mn |
| Dec 31, 2020 | 41.57 Mn |
| Sep 30, 2020 | 34.89 Mn |
| Jun 30, 2020 | 32.46 Mn |
| Mar 31, 2020 | 27.00 Mn |